Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial L. Paracchini, A. Velle, P. Di Gennaro, L. Mannarino, L. Ancona, D. Lorusso, S.C. Cecere, N. Colombo, L. Beltrame, A. Fagotti, G. Tasca, M. Piemontese, L. Arenare, D. Califano, F. Galdiero, R. Zadro, P. Chiodini, F. Perrone, E. Biagioli, M. D’Incalci, C. Romualdi, S. Pignata, S. Marchini ESMO Open, 2026 BACKGROUND: Advanced-stage epithelial ovarian cancer (EOC) remains a therapeutic challenge due to high relapse rates and limited survival, while standard post-surgical parameters such as residual tumor (RT) incompletely capture minimal residual disease (MRD) and offer limited insight into tumor evolution. To address this gap, we investigated whether a multimodal, tumor-agnostic analysis of circulating tumor DNA (ctDNA)-integrating tumor fraction (TF) and genome-wide fragmentomic profiles (PF)-could refine early risk stratification after cytoreductive surgery and enable longitudinal monitoring during therapy. MATERIALS AND METHODS: A total of 393 plasma samples from 173 patients in the phase IV MITO16a/MaNGO-OV2a trial were analyzed by shallow whole-genome sequencing at three time points: post-surgery/pre-chemotherapy (B1), post-chemotherapy (B2), and at the end of maintenance therapy or upon disease progression during maintenance (B3). Associations with progression-free survival (PFS) and overall survival (OS) were assessed using multivariable Cox models adjusted for clinical covariates. RESULTS: TF was detectable in 97% of patients at B1, including those classified as optimally debulked, and outperformed established clinical covariates in predicting survival [PFS: hazard ratio (HR) 1.02, P = 0.008; OS: HR 1.04, P = 0.005]. PF provided independent prognostic values (PFS: HR 1.06, P = 0.010; OS: HR 1.10, P = 0.005), and combined TF/PF modeling identified subgroups with distinct survival trajectories beyond clinical predictors (PFS: HR 1.76, P = 0.015; OS: HR 2.06, P = 0.029). Longitudinal copy number profiling revealed dynamic remodeling under treatment pressure, with recurrent 19q13.42 amplification emerging at B2 and B3. CONCLUSIONS: Together, these findings establish multimodal ctDNA profiling as a sensitive, non-invasive strategy for MRD detection and longitudinal surveillance in advanced EOC, refining prognostic assessment beyond clinical and surgical factors while paving the way for precision-guided therapeutic management.
Stage IVB ovarian carcinosarcoma in BRCA wild-type patients: two case reports of unexpected long-term remission Orazio De Tommasi, Sofia Bigardi, Angela Guerriero, Giulia Tasca, Davide Massa, Giulia Spagnol, Margherita Nardin, Marco Noventa, Carlo Saccardi, Roberto Tozzi Frontiers in Oncology, 2026 Background Ovarian carcinosarcoma (OCS), also known as malignant mixed Müllerian tumor, is a rare and highly aggressive subtype of epithelial ovarian cancer, accounting for less than 4% of all cases. It typically presents at advanced stages and is associated with dismal outcomes, with a five-year survival rate below 30%. Despite improvements in cytoreductive surgery and systemic therapies, long-term survival in stage IV disease remains exceedingly uncommon. Case presentation We report two exceptional cases of stage IVB Müllerian carcinosarcoma occurring in BRCA wild-type postmenopausal women who achieved prolonged complete remission exceeding five years after multimodal management. The first patient, aged 61, presented with bilateral adnexal masses and a solitary pulmonary metastasis. She underwent primary cytoreductive surgery including hysterectomy, bilateral adnexectomy, lymphadenectomy, appendicectomy, and omentectomy, followed by six cycles of platinum-taxane chemotherapy. Residual pulmonary disease was later removed via video-assisted thoracoscopic lobectomy, confirming metastatic OCS. Post-recurrence, she received off-label maintenance with tamoxifen 20 mg daily for five years and remains disease-free at 70 months. The second patient, aged 70, presented with a pelvic mass invading the recto-sigmoid wall and a synchronous hepatic metastasis. She underwent extensive cytoreductive surgery including hysterectomy, en-bloc rectal resection, lymphadenectomy, cholecystectomy, and liver wedge resection, achieving complete macroscopic cytoreduction. Histology confirmed a Müllerian carcinosarcoma with a predominant endometrioid component. Postoperative chemotherapy with carboplatin-paclitaxel was followed by maintenance niraparib 100 mg twice daily for three years. She remains in complete remission at 60 months. Discussion Both patients demonstrate durable disease control in the absence of germline or somatic BRCA mutations, suggesting that long-term remission may be achievable even in BRCA-wild-type OCS through optimal surgery and individualized maintenance approaches. Tamoxifen, rarely employed in this setting, may have provided estrogen-receptor-mediated tumor suppression in the first case, while the second case highlights potential activity of PARP inhibition beyond BRCA mutation carriers. Conclusion These two reports challenge the long-held perception of uniformly poor outcomes in metastatic ovarian carcinosarcoma. Complete cytoreductive surgery combined with tailored systemic and maintenance therapies can achieve sustained remission even in advanced-stage BRCA-wild-type patients. Broader molecular profiling and international collaboration are essential to refine management strategies for this rare and aggressive malignancy.
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal malignancies: a monocentric, single-arm open-label phase II clinical trial Marco Tonello, Carola Cenzi, Paola Del Bianco, Elisa Pizzolato, Chiara Maria Biatta, Francesca Bergamo, Giulia Tasca, Anna Roma, Selma Ahcene Djaballah, Beatrice Bordignon, Giovanna Magni, Giacomo Moratello, Gaetano Ramondo, Sara Lonardi, Pierluigi Pilati, Antonio Sommariva, Gian Luca De Salvo Surgical Oncology, 2025 Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a promising palliative treatment for patients with peritoneal malignancies who are not candidates for curative surgery. This study aimed to assess the efficacy and feasibility of implementing a PIPAC program at a single cancer center. An open-label, single-arm, phase II study was conducted, enrolling patients with peritoneal tumors of various origins. Participants received bidirectional chemotherapy (intravenous and PIPAC). The primary endpoint was PIPAC efficacy measured as pathological response, while secondary endpoints included safety and feasibility of the technique, quality of life, and clinical outcomes. From March 2021 to March 2024, 32 patients were screened, and 25 were enrolled, resulting in 58 PIPAC procedures. The complication rate was low, with severe surgical complications occurring in 1.7 % of procedures and CTCAE grade 3 complications in 3.4 %. A major pathological response was observed in 56 % of cases, and seven patients (28.0 %) underwent curative-intent cytoreductive surgery after at least two PIPAC treatments. Both the Peritoneal Cancer Index (PCI) and the Peritoneal Regression Score (PRGS) decreased after repeated PIPAC (p = 0.016 and p = 0.047, respectively). Ascites volume also decreased significantly after the first PIPAC (p = 0.001). The median overall survival (OS) was 9.6 months, with responding patients (PRGS 1–2) showing better clinical outcomes (OS: 21.0 vs. 5.5 months,p < 0.001; PFS: 8.2 vs. 2.4 months,p < 0.001) and quality of life (p = 0.003). PIPAC can be safely combined with systemic chemotherapy in patients with peritoneal malignancies, demonstrating efficacy in controlling ascites and achieving major pathological response. Further studies are necessary to determine its potential survival benefits. • PIPAC combined with systemic chemotherapy is safe and feasible in peritoneal metastases. • Major pathological response (PRGS 1–2) was observed in 56 % of treated patients. • Repeated PIPAC are associated with reduced PCI and ascites volume and improved PRGS. • Adding PIPAC to systemic chemotherapy did not negatively impact patient-reported QoL. • Patients with major pathological response after PIPAC reported better QoL outcomes.
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial Eliana Pivetta, Vincenzo Canzonieri, Marina Bagnoli, Paolo Chiodini, Anna Spina, Laura Arenare, Domenica Lorusso, Giulia Tasca, Sabrina C. Cecere, Annamaria Ferrero, Giosuè Scognamiglio, Francesca Basso-Valentina, Daniela Califano, Loris De Cecco, Teresa Di Lauro, Milena S. Nicoloso, Martina Arcieri, Daniela Russo, Paola Spessotto, Stefano Indraccolo, Delia Mezzanzanica, Francesco Perrone, Sandro Pignata, Gustavo Baldassarre Npj Precision Oncology, 2025 The treatment of Epithelial Ovarian cancer (EOC) could benefit from the addition of bevacizumab (BEV) to standard chemotherapy in selected patients. Gene expression (GE) profiling and the evaluation of immune infiltration are used to define patients' prognosis. However, their role as prognostic and/or predictive biomarkers for the efficacy of antiangiogenic therapy efficacy remains uncertain. In this study, we combined GE profiling and multiplex immunofluorescence (MIF) analyses on material from patients enrolled in the phase IV MITO16A/MaNGO OV-2 trial, assessing associations between immune infiltrate and patients' prognosis. Patients were stratified into four molecular subtypes, and CIBERSORTx was applied to infer the cell-type-specific expression pattern of immune populations. MIF evaluated the presence of immune cells in the tumor and stromal compartments. These complementary experimental approaches revealed that immune infiltration is associated with shorter progression-free survival in BEV-treated patients, warranting future investigation to evaluate its use as a viable biomarker for patient stratification. Trial registration: NCT01706120, EudraCT number: 2012-003043-29, Date of registration 24 September 2012.
Early Gestational Choriocarcinoma: Report of two Cases and Review of the Literature Angela Guerriero, Lara Alessandrini, Luisa Santoro, Kathrin Ludwig, Vennus Shafiei, Pietro Goglia, Pava Srsen, Giulia Tasca, Angelo Paolo Dei Tos Pathologica, 2025 Gestational choriocarcinoma (GCC) is a malignant and aggressive tumor composed of neoplastic trophoblasts rarely arising months after a normal gestation or after an hydatidiform mole (HM). Histologically, its main diagnostic features are a trimorphic population of trophoblast cells and an absence of chorionic villi. Recently, extremely rare cases of GCC diagnosed in molar and in placenta specimens have been described and accepted as early forms of GCC. We report two cases of GCC diagnosed in a term placenta and in a complete HM (CHM) and underline the importance of recognizing such a rare early form of GCC.
PD-1 and PD-L1 Expression in Endometrial Cancer: A Systematic Review of the Literature Orazio De Tommasi, Matteo Marchetti, Marta Tripepi, Sofia Bigardi, Giosuè Giordano Incognito, Valentina Tuninetti, Emma Facchetti, Giulia Tasca, Marco Noventa, Carlo Saccardi, Roberto Tozzi, Giulia Spagnol Journal of Clinical Medicine, 2025 Background/Objectives: Cancer immunotherapy through the use of PD-1/PD-L1 inhibitors have shown significant promise in endometrial carcinoma (EC), particularly in tumors with microsatellite instability (MSI) or mismatch repair deficiency (dMMR), present in approximately 30% of cases. This review evaluated PD-L1 and PD-1 expression as potential biomarkers for immunotherapy response in EC, focusing on their relationship with MSI status. Methods: A systematic review, adhering to PRISMA guidelines, analyzed studies from MEDLINE and Embase until February 2023 on PD-1/PD-L1 expression in EC stratified by MSI status, including diverse study designs but excluding conference abstracts, with independent screening, data extraction, and additional reference checks to ensure comprehensive coverage. Results: A systematic analysis of 10 studies found that PD-L1 expression was more frequently expressed in MSI tumors (49%) compared to microsatellite-stable tumors (MSS) (33.5%), while PD-1 was expressed in 58% of MSI cases and 48% of MSS cases. Despite these findings, the prognostic value of PD-L1/PD-1 remains uncertain, with conflicting results regarding their association with survival outcomes. PD-L1 expression varied across molecular subtypes, being highest in POLE-mutated tumors (76.56%) and serous carcinomas (73%). Differences in PD-L1 expression between primary and metastatic sites were also noted, complicating its use as a biomarker. Conclusions: The assessment of PD-L1 expression in EC could represent a valuable option for selecting patients who may benefit from immune checkpoint inhibitors (ICI), including those in the MSS cohort, thereby ensuring a more tailored and personalized treatment strategy.
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer Katherine Elizabeth Francis, Sandy Simon, Val Gebski, Florence Joly, Jonathan A. Ledermann, Richard T. Penson, Amit M. Oza, Jacob Korach, Nuria Lainez, Sabrina Chiara Cecere, Giulia Tasca, Martina Gropp-Meier, Keiichi Fujiwara, Elizabeth S. Lowe, Michael Friedlander, Eric Pujade-Lauraine, Chee Khoon Lee Gynecologic Oncology, 2025 BACKGROUND: In women with platinum sensitive recurrent ovarian cancer (PSROC) undergoing maintenance treatment, adverse events (AEs) not attributable to the current treatment are not well understood. We used data from SOLO2/ENGOT-Ov21 to evaluate AEs reported in the placebo arm and to explore their longitudinal trajectories. METHODS: SOLO2/ENGOT-Ov21 (NCT01874353) randomly assigned 295 PSROC participants with a BRCA1/2 mutation to maintenance olaparib tablets (N = 196) or matching placebo (N = 99). For those assigned to placebo, we analyzed the AE (CTCAE v4.0) data including type, grade, time of onset and resolution, and attribution by investigator. RESULTS: Amongst 99 participants who received placebo 788 AEs were reported (95 % reporting ≥1 AE). Twenty-two percent of participants reported at least one grade ≥ 3 AE. Grade ≥ 2 AEs that persisted for over 100 days affected 21 % of participants. Recurring grade ≥ 1 AEs were experienced by 44 % of participants. Study investigators attributed 25 % of all AEs to the placebo treatment, with neutropenia (88 %), nausea (52 %) and thrombocytopenia (50 %) most attributed. Three percent of participants had a dose reduction, 19 % had treatment delays, and 2 % had permanent treatment discontinuation, due to AEs attributed to placebo. CONCLUSION: Virtually all PSROC participants in the SOLO2/ENGOT-Ov21 experienced one or more AE whilst on placebo. Furthermore, study investigators attributed one quarter of AEs to be related to placebo therapy and dose alterations and treatment changes were made based on these AE. Further work is needed to improve measurement and categorization of AEs in trials of maintenance therapy in PSROC.
The Role of Immunotherapy in MMR-Deficient Endometrial Carcinoma: State of the Art and Future Perspectives Matteo Marchetti, Jacopo Ferrari, Tommaso Vezzaro, Laura Masatti, Giulia Tasca, Tiziano Maggino, Roberto Tozzi, Carlo Saccardi, Marco Noventa, Giulia Spagnol Journal of Clinical Medicine, 2024 This study provides a comprehensive overview of the role of immunotherapy in the treatment of mismatch repair-deficient (MMRd) endometrial carcinomas. Immunotherapy has emerged as a transformative approach in the treatment of MMRd due to the high mutation rate and subsequent PD-1/PD-L1 overexpression seen in these tumors. This review analyzes the current landscape of existing randomized clinical trials, highlighting the efficacy of immune checkpoint inhibitors (ICIs) like pembrolizumab, avelumab, and dostarlimab. Additionally, the focus extends to the potential of combined therapeutic strategies, such as the integration of ICIs with targeted agents, while also exploring the application of immunotherapy in non-traditional settings beyond advanced or recurrent disease. This includes emerging roles in the adjuvant and neoadjuvant contexts to prevent recurrence and target early-stage disease. These findings underscore the importance of tailoring treatments based on the molecular characteristics of each tumor and paving the way for future advancements in the field of gynecologic oncology. Despite promising results, this article acknowledges the necessity of further research to refine patient selection criteria and explore combination strategies that can overcome resistance mechanisms.
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial Nicoletta Colombo, Elena Biagioli, Kenichi Harano, Francesca Galli, Emma Hudson, Yoland Antill, Chel Hun Choi, Manuela Rabaglio, Frederic Marmé, Christian Marth, Gabriella Parma, Lorena Fariñas-Madrid, Shin Nishio, Karen Allan, Yeh Chen Lee, Elisa Piovano, Beatriz Pardo, Satoshi Nakagawa, John McQueen, Claudio Zamagni, Luis Manso, Kazuhiro Takehara, Giulia Tasca, Annamaria Ferrero, Germana Tognon, Andrea Alberto Lissoni, Mariacristina Petrella, Maria Elena Laudani, Eliana Rulli, Sara Uggeri, M Pilar Barretina Ginesta, Paolo Zola, Claudia Casanova, Valentina Arcangeli, Lorenzo Antonuzzo, Angiolo Gadducci, Stefania Cosio, Andrew Clamp, Mojca Persic, Ian McNeish, Laura Tookman, Andrés Redondo Sanchez, Chel Hun Choi, Editta Baldini, Innocenza Palaia, Pierluigi Benedetti Panici, Nobutaka Takahashi, Janine Lombard, Antonio Ardizzoia, Alessandra Bologna, Ana Maria Herrero Ibáñez, Antonino Musolino, Raúl Márquez Vázquez, Klaus Pietzner, Elena Braicu, Viola A. Heinzelmann-Schwarz, Melanie Powell, Yoshihito Yokoyama, Sally Baron-Hay, Chiara Abeni, Cristina Martin Lorente, Juan Fernando Cueva, Fabian Trillsch, Florian Heitz, Beyhan Ataseven, Edgar Petru, MartinLeonhard Heubner, Azmat Hassanq Sadozye, Sidharth Dubey, Andrea Tazbirkova, Susan Tiley, Kathryn Chrystal, Sang Wun Kim, Mathias Fehr, Kate Scatchard, Anjana Anand, Alexandra Taylor, Hidemichi Watary, Takayuki Enomoto, Kosuke Yoshihara, Sudarsha Selva-Nayagam, Bhaskar Karki, Michelle Harrison, Kate Wilkinson, Jeffrey Goh, Amanda Glasgow, Lorraine Chantrill, Chulmin Lee, Alessandro Bertolini, Filomena Narducci, Giovanna Bellotti, Vittorio Fusco, Stefan Aebi, Maria Del Grande, Ilaria Colombo, Hideki Tokunaga, Shogo Shigeta, Geraldine Goss, Zhen Rong Siow, Christopher Steer, Hao Lin, Kwang-Beom Lee, Giovanni Di Meglio, Elena Massa, Elvira De Marino, Vincenzo Tortora, Isabel Palacio Vazquez, Kosuke Tsuji, Eiichiro Tominaga, Jeffrey Goh, Allison Black, Kyeong A So, Dong Hoon Suh, Keun Ho Lee, Yong Man Kim, Roldano Fossati, Luciano Carlucci, Massimo Barberis, Valter Torri, Anna Santoni Lancet Oncology, 2024
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial Cristin Roma, Riziero Esposito Abate, Alessandra Sacco, Daniela Califano, Laura Arenare, Francesca Bergantino, Carmela Pisano, Sabrina Chiara Cecere, Giovanni Scambia, Domenica Lorusso, Grazia Artioli, Giulia Tasca, Anna Spina, Daniela Russo, Angiolo Gadducci, Carmine De Angelis, Alessandra Bologna, Sergio Marchini, Ettore Domenico Capoluongo, Francesco Perrone, Sandro Pignata, Nicola Normanno European Journal of Cancer, 2024
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity Anna Passarelli, Vittoria Carbone, Sandro Pignata, Roberta Mazzeo, Domenica Lorusso, Giovanni Scambia, Stefania Canova, Teresa Di Palma, Giulia Tasca, Mara Mantiero, Emanuele Naglieri, Claudia Andreetta, Martina Rauso, Anna Elisabetta Brunetti, Letizia Laera, Chiara Abeni, Giuseppa Scandurra, Anna Rita Gambaro, Alessia Pastore, Carmelo Bengala, Marco Gunnellini, Alberto Farolfi, Maurizio Spinello, Michele Bartoletti Gynecologic Oncology, 2024
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, Guillermo Villacampa, Munetaka Takekuma, Ugo De Giorgi, Kristina Lindemann, Linn Woelber, Nicoletta Colombo, Linda Duska, Alexandra Leary, Ana Godoy-Ortiz, Shin Nishio, Antoine Angelergues, Maria Jesús Rubio, Lorena Fariñas-Madrid, Satoshi Yamaguchi, Domenica Lorusso, Isabelle Ray-Coquard, Luis Manso, Florence Joly, Jesús Alarcón, Philippe Follana, Ignacio Romero, Coriolan Lebreton, J Alejandro Pérez-Fidalgo, Mayu Yunokawa, Hanna Dahlstrand, Véronique D'Hondt, Leslie M Randall, Sophie Abadie-Lacourtoisie, Claudia Andreetta, Nerea Anzizar, Daiseuke Aoki, Maria-Pilar Barretina-Ginesta, Marco Battista, Charlotte Bellier, Anne Gry Bentzen, Dominique Berton, Bertrand Billemont, Line Bjørge, Maria Bjurberg, Destin Black, Alessandra Bologna, Elena Ioana Braicu, Claudia Casanova, Radoslav Chekerov, Annick Chevalier, Juan Fernando Cueva, Bastian Czogalla, Nicolas Delanoy, Dominik Denschlag, Oscar Derke, Michael Eichbaum, Takayuki Enomoto, Carmen Esteban, Michel Fabbro, Tanja Fehm, Annamaria Ferrero, Markus Fleisch, Anne Floquet, Antonio Frassoldati, Lydia Gaba, Angiolo Gadducci, Yolanda García, Elena Geuna, Eva Guerra, Lars Hanker, Anne-Claire Hardy-Bessard, Philipp Harter, Kosei Hasegawa, Kristina Hellman, Ana Herrero, Felix Hilpert, Dionyssios Katsaros, Matthias Koegel, Anthoula Koliadi, Jean-Emmanuel Kurtz, Bjoern Lampe, Andrea Alberto Lissoni, Alain Lortholary, Giorgia Mangili, Laura Mansi, Frederik Marmé, Cara Mathews, William Mina, Shinichiro Minobe, Katherine Moxley, Shoji Nagao, Ornella Nicoletto, Koji Nishino, Hiroshi Nishio, Shin Nishio, Ana Oaknin, Michaela Onstad, Beatriz Pardo, J Alejandro Pérez-Fidalgo, Carmela Pisano, Andrés Poveda, Julia Radosa, Leslie M. Randall, Isabelle Ray-Coquard, Andrés Redondo, Debra Richardson, Ignacio Romero, Graziana Ronzino, Maria Jesús Rubio, Frederic Selle, Munetaka Takekuma, Nobuhiro Takeshima, Giulia Tasca, Krishnansu Tewari, Yukiharu Todo, Giorgio Valabrega, Pauline Wimberger, Linn Woelber, Satoshi Yamaguchi, Benoît You, Mayu Yunokawa Lancet, 2024
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line N. Colombo, A. Gadducci, J. Sehouli, E. Rulli, J. Mäenpää, C. Sessa, A. Montes, N. B. Ottevanger, R. Berger, I. Vergote, M. D’Incalci, C. Churruca Galaz, R. Chekerov, G. B. Nyvang, S. Riniker, R. Herbertson, R. Fossati, M. P. Barretina-Ginesta, M. Deryal, M. R. Mirza, E. Biagioli, M. Iglesias, G. Funari, M. Romeo, G. Tasca, B. Pardo, G. Tognon, M. J. Rubio-Pérez, A. DeCensi, U. De Giorgi, P. Zola, P. Benedetti Panici, M. Aglietta, V. Arcangeli, C. Zamagni, A. Bologna, A. Westermann, V. Heinzelmann-Schwarz, I. Tsibulak, P. Wimberger, A. Poveda, , , Nicoletta Colombo, Angiolo Gadducci, Eliana Rulli, Elena Biagioli, Roldano Fossati, Giuseppe Funari, Luciano Carlucci, Davide Poli, Maria Clara Caudana, Giulia Tasca, Maria Ornella Nicoletto, Germana Tognon, Andrea DeCensi, Ugo De Giorgi, Paolo Zola, Dionyssios Katsaros, Pierluigi Benedetti Panici, Innocenza Palaia, Massimo Aglietta, Valentina Arcangeli, Claudio Zamagni, Alessandra Bologna, Alessandro Bertolini, Cinzia Caroti, Milena Bruzzone, Nicoletta Donadello, Gianna Di Costanzo, Alberto Zaniboni, Daniela Surico, Roberta Buosi, Enrico Cortesi, Elena Zafarana, Vittorio Fusco, Laura Zavallone, Teresa Gamucci, Filomena Narducci, Valentina Musacchi, Luciana Babilonti, Annamaria Ferrero, Luigi Cavanna, Roberto Sabbatini, Stefano Tamberi, Maria Rosa Gentili, Grazia Artioli, Antonio Ardizzoia, Alessia Caldara, Zuzana Sirotovà, Clelia Casartelli, Michele Aieta, Saverio Cinieri, Elvira De Marino, Stefania Gori, Francesco Ferraù, Livio Blasi, Massimiliano Alù, Sabino De Placido, Carlo Milandri, , Cristina Churruca Galaz, Maria Pilar Barretina-Ginesta, Isabel Bover, Margarita Romeo, Beatriz Pardo, Maria Jesus Rubio-Pèrez, Andrés Poveda, Ana Santaballa, Raúl Márquez, Jesus Alarcon, Cristina Caballero-Diaz, Nuria Ruiz Miravet, Eugenia Ortega, Maria Angels Arcusa Lanza, Silvia Catot Tort, Elena Garcia Martinez, Regina Girones, Yolanda Garcia, Cesar Mendiola, Ana Beatriz Sanchez, Elena Garcia Martinez, , Jalid Sehouli, Mustafa Deryal, Pauline Wimberger, Georg Heinrich, Ingo Runnebaum, Fabian Trillsch, Gülten Oskay-Özcelik, Maike de Wit, Eva-Maria Grischke, Dirk Bauerschlag, Florian Heitz, Alexander Mustea, Tanja Fehm, Andrea Heider, Max Dieterich, Martina Groop-Meier, Marco Battista, Achim Woeckel, Ivo Meinhold-Heerlein, , Ana Montes, Rebecca Herbertson, Emma Hudson, Rebecca Bowen, , Ignace Vergote, Lionel D’Hondt, Peter Vuylsteke, Christof Vulsteke, , Petronella-Beatrix Ottevanger, Anneke M. Westermann, , Cristiana Sessa, Salome Riniker, Viola Heinzelmann-Schwarz, Roger Von Moos, Elena Kralidis, Michael Mueller, Stefan Aebi, Catrina Uhlmann Nussbaum, Mathias Fehr, Andreas Müller, Christian Taverna, , Johanna Mäenpää, Gitte-Bettina Nyvang, Mansoor Raza Mirza, Gunnar B. Kristensen, Anne Gry Bentzen, Bent Fiane, Ulla Puistola, Maarit Anttila, , Christian Marth, Regina Berger, Edgar Petru, Christian Schauer, Alexander Reinthaller British Journal of Cancer, 2023
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial E.D. Capoluongo, B. Pellegrino, L. Arenare, D. Califano, G. Scambia, L. Beltrame, V. Serra, G.L. Scaglione, A. Spina, S.C. Cecere, R. De Cecio, N. Normanno, N. Colombo, D. Lorusso, D. Russo, C. Nardelli, M. D’Incalci, A. Llop-Guevara, C. Pisano, G. Baldassarre, D. Mezzanzanica, G. Artioli, M. Setaro, G. Tasca, C. Roma, N. Campanini, S. Cinieri, A. Sergi, A. Musolino, F. Perrone, P. Chiodini, S. Marchini, S. Pignata ESMO Open, 2022
Prognostic factors in phyllodes tumours of the breast: Retrospective study on 166 consecutive cases Elisabetta Di Liso, Michele Bottosso, Marcello Lo Mele, Vassilena Tsvetkova, Maria Vittoria Dieci, Federica Miglietta, Cristina Falci, Giovanni Faggioni, Giulia Tasca, Carlo Alberto Giorgi, Tommaso Giarratano, Eleonora Mioranza, Silvia Michieletto, Tania Saibene, Angelo Paolo Dei Tos, PierFranco Conte, Valentina Guarneri ESMO Open, 2020
Immune characterization of breast cancer metastases: Prognostic implications Maria Vittoria Dieci, Vassilena Tsvetkova, Enrico Orvieto, Federico Piacentini, Guido Ficarra, Gaia Griguolo, Federica Miglietta, Tommaso Giarratano, Claudia Omarini, Serena Bonaguro, Rocco Cappellesso, Camillo Aliberti, Grazia Vernaci, Carlo Alberto Giorgi, Giovanni Faggioni, Giulia Tasca, Pierfranco Conte, Valentina Guarneri Breast Cancer Research, 2018
